Interferons and their application in the diseases of the lung

Chest

Volumn 123, Issue 1, 2003, Pages 209-216

  Antoniou, Katerina M ^a,b   Ferdoutsis, Emmanouil ^a,b   Bouros, Demosthenes ^c,d  

^a Nephrology Department   (Greece)

^b UNIVERSITY HOSPITAL OF IRAKLION   (Greece)

^c DEMOCRITUS UNIVERSITY OF THRACE MEDICAL SCHOOL   (Greece)

^d University General Hospital   (Greece)

Author keywords

Interferon ; Interferon ; Interferon ; Interferons; Pulmonary disease; Therapy; Treatment

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ALPHA2C INTERFERON; ANTIMYCOBACTERIAL AGENT; ANTINEOPLASTIC AGENT; BETA1A INTERFERON; CISPLATIN; DOXORUBICIN; PLATINUM DERIVATIVE; PREDNISOLONE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT GAMMA INTERFERON; RETINOIC ACID;

ANOREXIA; AUTOIMMUNE DISEASE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; FATIGUE; FEVER; HEADACHE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOTHERAPY; IMMUNOTOXICITY; INTERSTITIAL LUNG DISEASE; LUNG CARCINOMA; LUNG DISEASE; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUPUS ERYTHEMATOSUS; MALAISE; MALIGNANT MESOTHELIOMA; MYALGIA; NEUROTOXICITY; NONHUMAN; PLEURA EFFUSION; POLYARTHRITIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SKIN TOXICITY; VEIN THROMBOSIS; WEIGHT REDUCTION;

EID: 0037249039     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.123.1.209     Document Type: Review

References (58)

1. Le Page C, Genin P, Baines MG, et al. Interferon activation and innate immunity. Rev Immunogenet 2000; 2:374-386
2. Oritani K, Kincade PW, Zhang C, et al. Type I interferons and limitin: a comparison of structures, receptors, and functions. Cytokine Growth Factor Rev 2001; 12:337-348
3. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA 1994; 91:1198-1205
4. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biologic clinical applications, and toxicities. Oncologist 2001; 6:34-55
5. Sen GC, Lengyel PJ. The interferon system: a bird's eye view of its biochemistry. J Biol Chem 1992; 267:5017-5020
6. Nathan C, Sporn MJ. Cytokines in context. J Cell Biol 1991; 113:981-986
7. De Maeyer E, De Maeyer-Guignard J. Type I interferons. Int Rev Immunol 1998; 17:53-73
8. Gresser I. Antitumour effects of interferons: past, present and future Br J Haematol 1991; 79(suppl):1-5
9. Gallin JI, Farber JM, Holland SM, et al. Interferon-γ in the management of infectious diseases. Ann Intern Med 1995; 123:216-219
10. Granstein RD, Murphy GF, Margolis RJ, et al. Gamma-interferon inhibits collagen synthesis in vivo in the mouse. J Clin Invest 1987; 79:1254-1258
11. Jaffe HA, Gao Z, Mori Y, et al. Selective inhibition of collagen gene expression in fibroblasts by an interferon-gamma transgene. Exp Lung Res 1999; 25:199-215
12. Berkman N, Kremer S, Or R, et al. Recombinant interferon-alpha2a and interferon-alphaA/D have different effects on bleomycin-induced lung injury. Respiration 2001; 68:169-177
13. Raghu G, Bozic CR, Brown K, et al. Feasibility of a trial of interferon beta-1A (IFN b-1a) in the treatment of idiopathic pulmonary fibrosis (IPF) [abstract]. Am J Respir Crit Care Med 2001; 163:A707
14. Ziesche R, Hofbauer E, Wittmann K, et al. A preliminary study of long-term treatment with interferon gamma-1b and low dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999; 341:1264-1269
15. Gurujeyalakshmi G, Giri SN. Molecular mechanisms of anti-fibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: down-regulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res 1995; 21:791-808
16. Ulloa L, Doody J, Massague J. Inhibition of transforming growth factor-beta/SMAD signaling by the interferon-gamma/STAT pathway. Nature 1999; 397:710-713
17. du Bois RM. Interferon gamma-1b for the treatment of idiopathic pulmonary fibrosis. N Engl J Med 1999; 341:1302-1304
18. King TE Jr. Interferon gamma-1b for the treatment of idiopathic pulmonary fibrosis [letter]. N Engl J Med 2000; 342:975
19. Raghu G, Brown K, Noble PW, et al. Interferon gamma-1b in idiopathic pulmonary fibrosis: reanalysis of a published study; continuing education series. Atlanta, GA: American Thoracic Society, 2000; 44-51
20. Raghu G, Spada G, Otaki Y, et al. Interferon gamma in the treatment of advanced idiopathic pulmonary fibrosis and fibrotic nonspecific interstitial pneumonia (NSIP): prospective, preliminary clinical observations in one center [abstract]. Chest 2001; 120:(suppl):185
21. Antoniou KM, Bouros D, Sourvinos G, et al. A multicenter randomized comparative trial of long-term treatment with interferon gamma-1b vs colchicine in patients with idiopathic pulmonary fibrosis. Paper presented at 3rd Mediterranean Congress on Thoracic Diseases. Crete, Hellas, Greece, November 1-4, 2000; 138
22. Veys EM, Mielants H, Verbruggen G, et al. Interferon gamma in rheumatoid arthritis: a double blind study comparing human recombinant interferon gamma with placebo. J Rheumatol 1988; 15:570-574
23. Cannon GW, Pincus SH, Emkey RD, et al. Double blind trial of recombinant gamma-interferon vs placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 1989; 32:964-973
24. Lemmel EM, Brackertz D, Franke M, et al. Results of a multicenter placebo-controlled double-blind randomized phase III clinical study of rheumatoid arthritis with recombinant interferon-gamma. Rheumatol Int 1988; 8:87-93
25. Hein R, Behr J, Hundgen M, et al. Treatment of systemic sclerosis with interferon-gamma. Br J Dermatol 1992; 126: 496-501
26. Grassegger A, Schuler G, Hessenberger G, et al. Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial. Br J Dermatol 1998; 139:639-648
27. Shepherd FA. Alternatives to chemotherapy and radiotherapy in the treatment of small cell lung cancer. Semin Oncol 2001; 28:30-37
28. Bitran JD, Green M, Perry M, et al. A phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer. Am J Clin Oncol 1995; 18:67-70
29. van Zandwijk N, Groen HJ, Postmus PE, et al. Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer: a randomised phase III study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer 1997; 33:1759-1766
30. Prior C, Oroszy S, Oberaigner W, et al. Adjunctive interferon-alpha-2c in stage IIIB/IV small-cell lung cancer: a phase III trial. Eur Respir J 1997; 10:392-396
31. Ruotsalainen T, Halme M, Isokangas OP, et al. Interferon-alpha, and 13-cis-retinoic acid as maintenance therapy after high-dose combination chemotherapy with growth factor support for small cell lung cancer-a feasibility study. Anticancer Drugs 2000; 11:101-108
32. Ruotsalainen TM, Halme M, Tamminen K, et al. Concomitant chemotherapy and IFN-alpha for small cell lung cancer: a randomized multicenter phase III study. J Interferon Cytokine Res 1999; 19:253-259
33. Halme M, Maasilta PK, Pyrhonen SO, et al. Interferons combined with chemotherapy in the treatment of stage III-IV non-small cell lung cancer: a randomized study. Eur J Cancer 1994; 30:11-15
34. Antman KH. Natural history and epidemiology of malignant mesothelioma. Chest 1993; 103:373-376
35. Butchart EG, Ashcroft T, Barnsley WC, et al. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura: experience with 29 patients. Thorax 1976; 31:15-24
36. Boutin C, Viallat JR, Van Zandwijk N, et al. Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma. Cancer 1991; 67:2033-2037
37. Boutin C, Nussbaum E, Monnet I, et al. Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 1994; 74:2460-2467
38. Monti G, Jaurand MC, Monnet I, et al. Intrapleural production of interleukin 6 during mesothelioma and its modulation by γ-interferon treatment. Cancer Res 1994; 54:4419-4423
39. Parra HS, Tixi L, Latteri F, et al. Combined regimen of cisplatin, doxorubicin, and a-2b interferon in treatment of advanced malignant pleural mesothelioma. Cancer 2001; 92:650-656
40. Marel M, Zrustova M, Stasny B, et al. The incidence of pleural effusion in a well-defined region: epidemiologic study in central Bohemia. Chest 1993; 104:1486-1489
41. Casali A, Gionfra T, Rinaldi M, et al. Treatment of malignant pleural effusions with intracavitary Corynebacterium parvum. Cancer 1988; 62:806-811
42. Goldman CA, Skinnider LF, Maksymiuk AW. Interferon instillation for malignant pleural effusion. Ann Oncol 1993; 4:141-145
43. Yanagawa H, Sone S, Nii A, et al. Lymphokine-activated killer induction and its regulation by macrophages in malignant pleural effusion. Jpn J Cancer Res 1989; 80:1220-1227
44. Wilkins H, Connolly M, Grays P, et al. Recombinant interferon alpha-2b in the management of malignant pleural effusions. Chest 1997; 111:1597-1599
45. Rosso R, Rimondi R, Salvati F, et al. Intrapleural natural beta interferon in the treatment of malignant pleural effusions. Oncology 1988; 45:253-256
46. Goldman CA, Skinnider LF, Maksymiuk AW. Interferon instillation for malignant pleural effusions. Ann Oncol 1993; 4:141-145
47. Ferdoutsis E, Bouros D, Meletis G, et al. A comparative study of intrapleural a2-interferon (a2-IFN) vs γ-interferon (γ-IFN) in the control of malignant pleural effusions [abstract]. Eur Respir J 1996; 9(suppl):459s
48. Ferdoutsis E, Bouros D, Meletis G, et al. A comparative study of intrapleural instillation of bleomycin vs a2-interferon on the control of malignant pleural effusions. Eur Respir J 1994; 7(suppl):412s
49. Yanagawa H, Haku T, Hiramatsu K, et al. Intrapleural instillation of interferon γ in patients with malignant pleurisy due to lung cancer. Cancer Immunol Immunother 1997; 45:93-99
50. Goble M, Iseman MD, Madsen LA, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328:527-532
51. Condos R, Rom WN, Schluger N. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-γ via aerosol. Lancet 1997; 349:1513-1515
52. Holland SM, Eisenstein EM, Kuhns DB, et al. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma: a preliminary report. N Engl Med 1994; 12:1348-1355
53. Bonecini-Almeida G, Chitale S, Boutsikakis I, et al. Induction of in vitro human macrophage anti-mycobacterium tuberculosis activity: requirement for IFN-γ and primed lymphocytes. J Immunol 1998; 160:4490-4499
54. Pietropaoli A, Modrak J, Utell M. Interferon-a therapy associated with the development of sarcoidosis. Chest 1999; 116:569-572
55. Ravenel J, McAdams P, Plankeel J, et al. Sarcoidosis induced by interferon therapy. AJR Am J Roentgenol 2001; 177:199-201
56. Vander Els NJ, Gerdes H. Sarcoidosis and IFN-alpha treatment [letter]. Chest 2000; 117:294
57. Steinmann GG, Rosenkaimer F, Gerhard L. Clinical experiences with interferon-alpha and interferon-gamma. Int Rev Exp Pathol 1993; 34:193-207
58. Bouros D, Antoniou KM, Siafakas NM. Deep venous thrombosis in a patient treated with interferon-γ [letter]. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18:201